For most of 2023 and 2024, the pitch for compounded GLP-1s was a single number: the same molecule, for a tenth of the price. A telehealth site would sell you compounded semaglutide for around $200 a month while the branded pen carried a list price north of $1,300. That gap — call it the spread — was the entire business model of the compounding era.
In 2026 the spread has collapsed, and almost nobody is charting how far. Here is the number that matters. The gray-market discount that once ran roughly ten to one is now closer to two to one, and at some doses it has essentially vanished. Not because compounders raised prices — they didn't — but because Eli Lilly and Novo Nordisk finally cut their own cash prices to strangle the copycats.
My thesis: the manufacturers spent a decade refusing to compete on price, and the popular version of this story is a year out of date. "Compounded is way cheaper" was true in 2023. In 2026 it is a claim that needs an asterisk the size of the page — and the asterisk is the most interesting part of the whole chart.
Compounding, briefly, so the numbers make sense. Under sections 503A and 503B of the Food, Drug, and Cosmetic Act, pharmacies can legally make copies of a drug while it sits on the FDA's official shortage list. Semaglutide and tirzepatide were both on that list from 2022 through late 2024. That window is what let telehealth companies — Hims, Ro, and hundreds of smaller compounding pharmacies — sell mass-produced "compounded" versions at a fraction of brand price. It was never quite a loophole; it was a temporary legal exception, and everyone building on it knew the clock was running.
The spread as it was
When the shortage exception was open, the arithmetic was brutal for the brands. Wegovy carried a list price around $1,349 a month. Zepbound's list ran about $1,060. Ozempic sat near $969, Mounjaro around $1,069. Against those numbers, a compounded vial of semaglutide at $150 to $300 a month — sometimes fronted by a $99 introductory offer — looked like a different category of product entirely.
Cash-pay patients, and there were millions of them once insurers started refusing coverage, did the only rational thing and bought the copy. At its widest, the spread was five to seven times. In marketing it got rounded up to "ten times cheaper." That rounding was doing work, but the direction was real, and for two years it moved enormous volume out of the branded channel.
What closed the gap wasn't the crackdown — it was the price cut
The obvious explanation is the FDA. Semaglutide came off the shortage list in February 2025; tirzepatide's resolution landed in late 2024. Mass 503B compounding of both molecules became illegal. Case closed. Except it isn't — because the crackdown alone would have pushed cash patients back toward $1,300 pens, and that is not what happened. What happened is that the drugmakers moved the floor.
Lilly expanded LillyDirect self-pay vials of Zepbound — single-dose vials at $349 for the starter dose and $499 for higher doses, sold cash, no insurance in the loop. Novo answered with a NovoCare cash channel offering Wegovy at $499 a month across doses. In eighteen months the brand cash price fell from roughly $1,300 to roughly $499 — a 60% cut the companies would have called unthinkable in 2023.
I think that is the single most underrated fact in the entire GLP-1 pricing story. The price war the manufacturers refused to fight against each other, they finally fought against their own gray market. The compounders didn't get undercut by a regulator. They got undercut by the brands.
So what is the spread now?
Chart it dose by dose and the picture is stark. The surviving compounded discount — now mostly personalized 503A preparations rather than the old mass-produced kind — runs roughly $200 to $300 a month. Brand cash-pay sits at $349 to $499. The spread has compressed from five-to-seven times down to something like 1.3-to-2 times.
At the starter-dose level, where a $349 LillyDirect vial meets a $250 compound, it is nearly gone. For a patient weighing a $349 vial made by Lilly under FDA oversight against a $250 preparation from a pharmacy whose legal footing just got shakier, the "discount" is now about $99 a month set against a real quality-and-legality gap. That is a genuinely different decision than the one people faced in 2023, and the chart is why.
In 2023 the choice was $200 versus $1,300. In 2026 it's $250 versus $499 — and one of those two options is now on far firmer legal and clinical ground than it used to be.
The counter-argument: the spread still matters where it always did
Let me argue against myself. The spread hasn't closed for everyone. For the genuinely cash-strapped, the difference between $250 and $499 is not trivia; it is whether the prescription gets filled at all. And the brand cash programs carry quiet limits — the cheapest LillyDirect vials sit at the lower doses, $499 is a monthly number with no copay assistance stacked behind it, and both run indefinitely. A personalized compound at $200 is still, for some people, the only version of this class they can reach.
There is also a molecule story the aggregate number hides. Brand tirzepatide cash-pay stays higher and stickier than semaglutide's, because Lilly holds the more effective drug and has less reason to discount it. Chart the spread by molecule rather than in aggregate and tirzepatide's gray-market discount held up better than semaglutide's — which tells you something about pricing power that a single blended figure erases.
Why the closing spread is the real story
Step back and the chart tells a market story, not a medical one. For three years the compounding industry lived in the gap between what these drugs cost to make and what the brands chose to charge. That gap was enormous, and it was a choice. The moment the manufacturers decided the gray market was a bigger threat than lost margin, they closed most of it themselves — faster and further than any regulator forced them to.
So when you read "compounded is cheaper," ask cheaper than what, and when. Against a 2023 list price, yes, dramatically. Against a 2026 LillyDirect vial, the honest answer is now "a little, sometimes, with an asterisk." The spread was the whole business model of the compounding era. Watching it close is watching that era end — not by ban, but by the one weapon the drugmakers had refused to use for a decade and finally did.
Ozemback — July 2026